Kratom and 7-OH in New Jersey: Schedule I Classification vs. Consumer Regulation

Summary: New Jersey is evaluating two opposing policy frameworks for kratom and 7-hydroxymitragynine (7-OH):
1. Criminalization via controlled substance scheduling versus;
2. Market oversight through product regulation.

• S301/A5359 (Criminalization Approach): Classifies 7-OH as a Schedule I controlled dangerous substance. Because it sets no concentration threshold, it does not distinguish concentrated/semi-synthetic 7-OH products from trace amounts naturally found in raw leaf kratom. Under existing CDS laws, unauthorized possession is a third-degree crime, while manufacture or distribution is a second- or third-degree crime depending on quantity.
• S1384/A4222 (Consumer Protection Approach): Regulates the commercial kratom market under the Department of Health. Sets age limits (21+), mandates lab testing and clear alkaloid labeling, caps 7-OH at 2% of total alkaloid content, and bans adulterants, synthetic alkaloids, and residual solvents. Violations primarily carry civil penalties, though third-offense non-compliance and sales to minors carry disorderly persons offenses.

Current Status (as of September 29, 2026):

• S301 passed the Senate Health Committee (8-0) and is in the Senate Budget and Appropriations Committee; A5359 was introduced in September 2026 and sent to the Assembly Judiciary Committee.
• S1384 is in the Senate Commerce Committee
• A4222 is in the Assembly Consumer Affairs Committee

Federal and Scientific Context: Both the FDA (2025) and DEA (2026 temporary scheduling proposal) differentiate concentrated, semi-synthetic 7-OH from traditional botanical kratom leaf, focusing restrictions on high-potency concentrates. Recent 2026 lab analysis indicates many commercial 7-OH products are semi-synthetically derived and often mislabeled.

Who will this affect?  

• Consumers and Community Members: Individuals using botanical kratom for pain, self-directed wellness, or opioid withdrawal face potential criminalization under S301/A5359 if natural leaf falls under the broad 7-OH umbrella. S1384/A4222 instead provides consumer safeguards, clear dosage labeling, and age restrictions.
• Behavioral Health and Harm Reduction Providers: S301/A5359 exposes businesses selling 7-OH or related products directly to criminal prosecution and asset penalties under state CDS laws. S1384/A4222 creates a regulated marketplace requiring product registration, testing, and compliance.
• Public and Legal Systems: S301/A5359 shifts primary oversight to law enforcement, prosecutors, courts, and corrections. S1384/A4222 places administrative and enforcement authority with the Department of Health and consumer protection agencies.

Central Policy Distinction

The choice before the Legislature is not whether 7-OH and kratom carry potential risk, but whether New Jersey addresses those risks primarily through criminal penalties and prohibition or through state-level public health standards and consumer product regulation.

What You Can Do

• Contact your state legislator to share your concerns or support regarding this legislation by bill number. 

• State you are a constituent: Include your home address, so the office knows you are a voter in their district. 

• Briefly explain how the bill would impact you personally or your local community.

Unsure who your representatives are? Use the Legislative Tracker on the New Jersey Legislature website.

You can also contact the Committee Chair and members as they decide if the bill moves forward.